Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | Prof. Siefker-Radtke on the EV-103 trial in bladder cancer

Arlene Siefker-Radtke, MD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses her thoughts on the latest news in bladder cancer at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain – the EV-103 trial of enfortumab vedotin combined with pembrolizumab (NCT03288545).